Related Experiment Video
Updated: Jun 16, 2026
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Dual angiotensin II and endothelin receptor antagonists
Chandrasekar Palaniswamy1, Dhana R Selvaraj, Dhamodaran Palaniappan
1Department of Medicine, New York Medical College, Valhalla, USA. drpchandrasekar@gmail.com
American Journal of Therapeutics
|January 23, 2010
Summary
Dual-acting blockers targeting both endothelin and angiotensin II show promise for treating hypertension. These agents reduce blood pressure and appear safe, with larger trials ongoing.
Area of Science:
- Cardiovascular Pharmacology
- Hypertension Research
Background:
- Endothelin and angiotensin II are key vasoconstrictors implicated in hypertension and organ damage.
- Dysregulation of these systems contributes to endothelial dysfunction and systemic hypertension.
Purpose of the Study:
- To evaluate the potential of dual-acting angiotensin II and endothelin receptor blockers as a novel antihypertensive therapy.
- To summarize preliminary safety and efficacy data for these agents.
Main Methods:
- Review of preclinical data in animal models.
- Analysis of preliminary human studies.
- Ongoing evaluation in larger randomized clinical trials.
Main Results:
- Dual-acting blockers effectively reduce systemic blood pressure in models and patients.
- Preliminary human data indicate good safety and tolerability.
- Larger trials are currently assessing comprehensive efficacy and safety profiles.
Conclusions:
- Dual-acting angiotensin II and endothelin receptor blockers represent a potential new class of antihypertensive medications.
- Further research and larger trials are warranted to confirm their therapeutic role.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...